- Home
- ABUS vs TALK Comparison
ABUS vs TALK Comparison
Compare ABUS & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- TALK
- Stock Information
- Founded
- ABUS N/A
- TALK 2012
- Country
- ABUS United States
- TALK United States
- Employees
- ABUS N/A
- TALK N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- TALK Medical/Nursing Services
- Sector
- ABUS Health Care
- TALK Health Care
- Exchange
- ABUS Nasdaq
- TALK Nasdaq
- Market Cap
- ABUS 697.3M
- TALK 576.9M
- IPO Year
- ABUS N/A
- TALK N/A
- Fundamental
- Price
- ABUS $3.21
- TALK $2.98
- Analyst Decision
- ABUS Strong Buy
- TALK Buy
- Analyst Count
- ABUS 4
- TALK 5
- Target Price
- ABUS $5.50
- TALK $4.38
- AVG Volume (30 Days)
- ABUS 903.4K
- TALK 1.5M
- Earning Date
- ABUS 11-06-2024
- TALK 10-29-2024
- Dividend Yield
- ABUS N/A
- TALK N/A
- EPS Growth
- ABUS N/A
- TALK N/A
- EPS
- ABUS N/A
- TALK N/A
- Revenue
- ABUS $6,742,000.00
- TALK $181,291,000.00
- Revenue This Year
- ABUS N/A
- TALK $28.09
- Revenue Next Year
- ABUS N/A
- TALK $22.76
- P/E Ratio
- ABUS N/A
- TALK N/A
- Revenue Growth
- ABUS N/A
- TALK 31.50
- 52 Week Low
- ABUS $2.21
- TALK $1.60
- 52 Week High
- ABUS $4.72
- TALK $3.92
- Technical
- Relative Strength Index (RSI)
- ABUS 33.77
- TALK 38.19
- Support Level
- ABUS $3.13
- TALK $3.20
- Resistance Level
- ABUS $3.61
- TALK $3.38
- Average True Range (ATR)
- ABUS 0.17
- TALK 0.17
- MACD
- ABUS -0.03
- TALK -0.07
- Stochastic Oscillator
- ABUS 12.12
- TALK 3.61
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.